Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Sequence of scfv for inhibiting hiv-1 virus infection and application thereof

A technology for HIV-1 and virus infection, which is applied in antiviral agents, antiviral immunoglobulins, and targeting specific cell fusion, etc., and can solve problems such as high HIV-1 mutation rate

Active Publication Date: 2021-02-26
SHENZHEN CITY OF REGENERATION BIOLOGICAL PHARMA TECH CO LTD
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] But HIV-1 has a high mutation rate, resulting in escape clones

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Sequence of scfv for inhibiting hiv-1 virus infection and application thereof
  • Sequence of scfv for inhibiting hiv-1 virus infection and application thereof
  • Sequence of scfv for inhibiting hiv-1 virus infection and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0034] A first aspect of the present invention provides:

[0035] A scFv protein for inhibiting HIV-1 virus infection, the sequence of the scFv protein is shown in SEQ ID NO.1-SEQ ID NO.9.

[0036] A second aspect of the present invention provides:

[0037] A CAR molecule that inhibits HIV-1 virus infection, the CAR molecule includes an extracellular antigen-binding domain and an intracellular domain, the extracellular antigen-binding domain is a scFv protein, and the sequence of the scFv protein is as shown in SEQ ID NO. 1~shown in SEQ ID NO.9.

[0038] In some examples of CAR molecules, the sequence of the intracellular domain is shown in SEQ ID NO.10.

[0039] A third aspect of the present invention provides:

[0040] A CAR-T cell that suppresses HIV-1 virus infection, the CAR-T cell is transduced with at least one CAR molecule, the CAR molecule includes an extracellular antigen binding domain and an intracellular domain, and the extracellular antigen The binding domain...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a scFv sequence for inhibiting HIV-1 virus infection and application thereof. Based on the variable region heavy chain (V) of HIV-1 neutralizing antibody VRC01 H ) and light chain (V L ), using its own method to connect its sequences to form scFv, and a total of 9 scFv molecules with high affinity to gp120 protein of HIV-1 were obtained. The scFv sequences of some examples of the present invention have good affinity to HIV-1 virus, and can effectively inhibit the virus from infecting target cells TZM-bl cells. Using the scFv sequences of some examples of the present invention, CAR-T cells that can inhibit HIV-1 virus infection can be constructed, and the CAR-T cells can strongly mediate the lysis of target cells and release LDH. The CAR-T cells of some examples of the present invention can better avoid the escape caused by HIV-1 virus mutation by loading multiple CAR molecules with different scFv sequences, and have a wider-spectrum HIV-1 virus inhibitory effect.

Description

technical field [0001] The invention relates to the technical field of cellular immunotherapy, in particular to scFv sequences for inhibiting HIV-1 virus infection and applications thereof. Background technique [0002] After human immunodeficiency virus type 1 (Human Immunodificiency Virus Type-1, HIV-1) infection, combined antiretroviral therapy (combined antiretroviral therapy, cART) can effectively inhibit virus replication. However, since the virus integrates in the infected cells and forms a stable latent infection reservoir, once the infected person stops cART treatment, the viremia flares up again in a short time, which constitutes a major obstacle to cure HIV-1 infection . [0003] The current research focus is to activate the latently infected virus through specific latent infection reversing agents (latency-reversing agents, LRAs), and then drug treatment or induce the body's immune system to kill infected cells. This intervention strategy is known as "shock and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K16/10C07K19/00C12N5/10A61K39/00A61P31/18
CPCA61P31/18A61K39/001102C07K14/7051C07K16/1045C07K2319/33
Inventor 张辉
Owner SHENZHEN CITY OF REGENERATION BIOLOGICAL PHARMA TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com